Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval. According to the National Cancer ...

A team of researchers from the Germans Trias i Pujol Research Institute (IGTP) and Institut Català d'Oncologia (ICO) has studied alterations in the KRAS gene in colorectal cancer by combining genomic ...

A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) compared with other variants, in part because the mutation appears to lead to ...

KRAS is the most frequently mutated oncogene across all human cancers. Although different KRAS mutations have long been thought to exert the same cancer-driving effects, a new study led by UT ...

KRAS is a small GTPase oncogene that, when mutated, drives aberrant signalling through the RAS–RAF–MEK–ERK cascade, promoting tumour cell proliferation, survival and metastatic dissemination. Roughly ...

Our cells rely on tightly regulated signaling pathways to control when they grow, divide and survive. When these regulatory systems are disrupted, cells can acquire the ability to grow uncontrollably ...

Mutations of KRAS have long been targets of interest for the development of new cancer therapies, but structural changes caused by these mutations have made it particularly difficult to target and ...

Results from the randomized phase 2 study (1801 Part 3B) of elraglusib plus gemcitabine/nab-paclitaxel (GnP) versus GnP in previously untreated metastatic pancreatic ...

Researchers at MUSC Hollings Cancer Center have discovered why a powerful cancer-causing gene mutation rarely appears in pancreatic tumors. The study, published in Cancer Research Communications, ...

Spatial molecular profiling of a resected pancreatic adenocarcinoma. Fluorescently-labeled probes bind to RNA targets to identify the location of different cell types within a tumor sample. A common ...